MEDX mit Super News - 500 Beiträge pro Seite
eröffnet am 20.09.04 12:25:55 von
neuester Beitrag 20.09.04 14:47:03 von
neuester Beitrag 20.09.04 14:47:03 von
Beiträge: 2
ID: 905.784
ID: 905.784
Aufrufe heute: 0
Gesamt: 503
Gesamt: 503
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 2351 | |
| vor 1 Stunde | 1649 | |
| heute 11:20 | 1589 | |
| heute 14:03 | 1522 | |
| heute 15:11 | 1171 | |
| heute 09:52 | 1156 | |
| vor 1 Stunde | 1153 | |
| vor 1 Stunde | 852 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.161,01 | +1,36 | 217 | |||
| 2. | 3. | 0,1885 | -0,26 | 90 | |||
| 3. | 2. | 1,1800 | -14,49 | 77 | |||
| 4. | 5. | 9,3500 | +1,14 | 60 | |||
| 5. | 4. | 168,29 | -1,11 | 50 | |||
| 6. | Neu! | 0,4400 | +3,53 | 36 | |||
| 7. | Neu! | 4,7950 | +6,91 | 34 | |||
| 8. | Neu! | 11,905 | +14,97 | 31 |
Feedback
Medarex Announces Major Antibody Strategic Alliance with Pfizer
Monday September 20, 6:00 am ET
Anti-CTLA-4 Patents Also Cross-Licensed
PRINCETON, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today a global collaboration with Pfizer, Inc. (NYSE: PFE - News) that provides for the discovery and development of up to 50 antibody products over ten years. The two companies also cross-licensed certain patents relating to their anti-CTLA-4 antibody programs. Pursuant to these agreements, Pfizer will make an initial cash payment to Medarex of $80 million and will purchase $30 million of Medarex`s common stock at a premium to the market price.
ADVERTISEMENT
Under the collaboration, Medarex expects to use its UltiMAb(TM) human antibody technology to create product candidates to disease-associated targets identified by Pfizer. Pfizer will be fully responsible for the worldwide development and commercialization of any products generated by the collaboration. Medarex has the potential to receive research funding, license fees and milestone payments, if certain milestones are met, exceeding $400 million if all 50 products obtain regulatory approval, as well as royalties on any commercial sales of the products.
Monday September 20, 6:00 am ET
Anti-CTLA-4 Patents Also Cross-Licensed
PRINCETON, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today a global collaboration with Pfizer, Inc. (NYSE: PFE - News) that provides for the discovery and development of up to 50 antibody products over ten years. The two companies also cross-licensed certain patents relating to their anti-CTLA-4 antibody programs. Pursuant to these agreements, Pfizer will make an initial cash payment to Medarex of $80 million and will purchase $30 million of Medarex`s common stock at a premium to the market price.
ADVERTISEMENT
Under the collaboration, Medarex expects to use its UltiMAb(TM) human antibody technology to create product candidates to disease-associated targets identified by Pfizer. Pfizer will be fully responsible for the worldwide development and commercialization of any products generated by the collaboration. Medarex has the potential to receive research funding, license fees and milestone payments, if certain milestones are met, exceeding $400 million if all 50 products obtain regulatory approval, as well as royalties on any commercial sales of the products.
und über 8 us
bezahlt, schade habe mch icht getraut
bezahlt, schade habe mch icht getraut 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 71 | ||
| 54 | ||
| 47 | ||
| 46 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 15 | ||
| 13 | ||
| 12 |
| Wertpapier | Beiträge | |
|---|---|---|
| 12 | ||
| 11 | ||
| 11 | ||
| 10 | ||
| 10 | ||
| 10 | ||
| 10 | ||
| 9 | ||
| 9 | ||
| 9 |
